Follow‐up of dermatological manifestations in non‐critical hospitalized patients with COVID‐19 pneumonia and their prognostic correlation with disease severity

García-Irigoyen, A; Acatitla-Acevedo, G A; Barrera-Godínez, Alejandro; Méndez‐Flores, Silvia; Domínguez-Cherit, J

doi:10.1111/jdv.17236

Cited by 3 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Retiform purpura in COVID-19 has been exclusively described in critically ill patients with multisystemic severe disease. [4][5][6]8,9 In this case, retiform purpura with extensive skin necrosis was the presenting and single manifestation of SARS-CoV-2 infection, with no pulmonary or additional impairment. Laboratorial findings were unspecific and excluded other possible causes of such cutaneous findings.…”

Section: Retiform Purpura and Extensive Skin Necrosis As The Single M...mentioning

confidence: 89%

Retiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection

Caldeira

Pestana

João

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Section: Retiform Purpura and Extensive Skin Necrosis As The Single M...mentioning

confidence: 89%

Retiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection

Caldeira

Pestana

João

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…Kutlu et al 34 speculated that itching, even if mild, in COVID‐19 patients might be a marker for the severity of the disease, for example, lung involvement. García‐Irigoyenetal 35 …”

Section: Cutaneous Reactionsmentioning

confidence: 99%

“…• mRNA-1273 (Moderna) • Anaphylaxis (0.0002-0.0005%) 14,18 • COVID arm (0.2-0.8%) 7 • Pityriasis rosea (0.4%) 35 • Urticaria (0.2%)7…”

Section: Mrna Vaccines • Bnt162b2mentioning

confidence: 99%

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

Temiz

Abdelmaksoud

Wollina

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute Respiratory Distress Syndrome. The safety profile of these vaccines needs is closely assessed. Methods This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords “coronavirus”, “COVID‐19”, “vaccine”, “cutaneous reactions”, “allergic reactions”, and “SARS‐CoV‐2”. Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021. Results In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS‐CoV‐2 vaccines currently available in the literature. As a result, although COVID‐19 vaccines can be reported to develop allergic and anaphylactic reactions, especially after m‐RNA vaccines, they remain at a low rate, and it is observed that these reactions may develop more frequently, especially in patients with previous allergies and mast cell disorders. Fortunately, these reactions are generally transient, benign, self‐limited. Conclusion Although there is still no definitive evidence, as dermatologists, we must be aware of the possibility of cutaneous reactions, newly diagnosed dermatoses, or exacerbation of existing dermatoses that may develop after the COVID‐19 vaccinations.

show abstract

“…A relação entre o tempo do aparecimento das lesões cutâneas e a infecção por SARS-CoV2 ainda é obscuro. Inicialmente foram descritos dois tipos clínicos característicos de manifestações na pele, como exantemas semelhantes ao quadro de infecções virais e lesões decorrentes de vasculopatias trombóticas, especialmente vasculite (Irigoyen et al, 2021).…”

Section: Introductionunclassified

“…Assim sendo, é possível muitas vezes associar o padrão da manifestação cutânea com a gravidade e mortalidade causada pela infecção viral (Irigoyen et al, 2021).…”

Section: Introductionunclassified

Manifestações cutâneas da COVID-19 em pacientes internados em um hospital universitário do Rio de Janeiro: estudo descritivo

Medeiros

López

Cardinelli

et al. 2023

RSD

View full text Add to dashboard Cite

Introdução: O coronavírus é uma doença infecciosa, que em sua apresentação clássica, causa uma infecção viral seguida de inflamação pulmonar e sistêmica, sendo observado em alguns pacientes além dos sintomas respiratórios, manifestações cutâneas. A gravidade e complexidade dos pacientes, determinaram também lesões por pressão (LP) inevitáveis, sendo relevante diagnóstico diferencial das lesões secundárias à COVID-19, especialmente livedóide e purpúrica. Objetivo: identificar as manifestações cutâneas encontradas nos registros de prontuários dos pacientes com COVID-19; descrever perfil dos pacientes acometidos por manifestações cutâneas relacionadas à COVID- 19; determinar taxa de incidência dessas lesões de pele na população analisada e descrever os principais cuidados preventivos para prevenção de lesões de pele. Método: estudo documental, retrospectivo, quantitativo, ocorrido entre os meses de setembro de 2021 e novembro de 2022 em um hospital universitário do Rio de Janeiro. Resultados: 596 pacientes analisados, sendo 98 deles com 155 lesões de pele diagnosticadas: 15 secundárias à COVID-19 - 09 (5,80%) livedóides, 03 (1,93%) cianoses e 03 (1,93%) lesões purpúricas, além de 111 (71,61%) LP e 29 (18,70%) lesões mistas. As LP apresentaram uma incidência de 18,62%, seguidas de lesões mistas, com taxa de 4,86% e lesões secundárias à COVID-19 com 2,51%. Conclusão: Lesões relacionadas à COVID-19 foram menos incidentes que as LP, confirmando a inevitabilidade referida pelo NPIAP. Diante disso, mais estudos epidemiológicos são necessários. Sobre os cuidados com a pele, medidas básicas de manutenção da sua integridade devem respeitar as boas práticas de higiene e hidratação.

show abstract

Follow‐up of dermatological manifestations in non‐critical hospitalized patients with COVID‐19 pneumonia and their prognostic correlation with disease severity

Cited by 3 publications

References 2 publications

Retiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection

Retiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

Manifestações cutâneas da COVID-19 em pacientes internados em um hospital universitário do Rio de Janeiro: estudo descritivo

Contact Info

Product

Resources

About